Dipentum
Loading...Dipentum Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
INDICATIONS AND USAGE: Olsalazine is indicated for the maintenance of remission of ulcerative colitis in patients who are intolerant of sulfasalazine.
History
There is currently no drug history available for this drug.
Other Information
DESCRIPTION: The active ingredient in DIPENTUM Capsules (olsalazine sodium) is the sodium salt of a salicylate, disodium 3,3'-azobis (6-hydroxybenzoate) a compound that is effectively bioconverted to 5-aminosalicylic acid (5-ASA), which has anti-inflammatory activity in ulcerative colitis. Its empirical formula is C14H8N2Na2O6 with a molecular weight of 346.21. The structural formula is:
Olsalazine sodium is a yellow crystalline powder, which melts with decomposition at 240°C. It is the sodium salt of a weak acid, soluble in water and DMSO, and practically insoluble in ethanol, chloroform, and ether. Olsalazine sodium has acceptable stability under acidic or basic conditions.
DIPENTUM is supplied in hard gelatin capsules for oral administration. The inert ingredient in each 250 mg capsule of olsalazine sodium is magnesium stearate. The capsule shell contains the following inactive ingredients: black iron oxide, caramel, gelatin, and titanium dioxide.
Sources
Dipentum Manufacturers
-
Meda Pharmaceuticals
![Dipentum (Olsalazine Sodium) Capsule, Gelatin Coated [Meda Pharmaceuticals]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Dipentum | Meda Pharmaceuticals
DOSAGE AND ADMINISTRATION: The usual dosage in adults for maintenance of remission is 1.0 g/day in two divided doses.
-
Ucb, Inc.
Dipentum | Ucb, Inc.
The usual dosage in adults for maintenance of remission is 1.0 g/day in two divided doses.
-
Alaven Pharmaceutical Llc
Dipentum | Alaven Pharmaceutical Llc
The usual dosage in adults for maintenance of remission is 1.0 g/day in two divided doses.
-
Carilion Materials Management
Dipentum | Carilion Materials Management
The usual dosage in adults for maintenance of remission is 1.0 g/day in two divided doses.
![Dipentum (Olsalazine Sodium) Capsule [Ucb, Inc.]](http://recallguide.cwdevelopsp.com/wp-content/themes/recallguide/assets/img/drug-image-placeholder.jpg)
![Dipentum (Olsalazine Sodium) Capsule, Gelatin Coated [Alaven Pharmaceutical Llc]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f4858879-0b8b-484a-9742-112c92662e8a&name=dipentum-02.jpg)
![Dipentum (Olsalazine Sodium) Capsule, Gelatin Coated [Carilion Materials Management]](http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=373c321f-cd33-4c11-a2d6-73f38384c27f&name=68151-3120.jpg)
Login To Your Free Account